Vitamin D deficiency and Alzheimer disease: Common links

Neurobiology of Disease

Volumn 84, Issue , 2015, Pages 84-98

  Keeney, Jeriel T ^a   Butterfield, D Allan ^b  

^a MICHIGAN STATE UNIVERSITY   (United States)

^b UNIVERSITY OF KENTUCKY   (United States)

Author keywords

Alzheimer's disease; Amyloid beta peptide; Deficiency; Signaling; Therapeutic intervention; Vitamin D

Indexed keywords

AMYLOID BETA PROTEIN; AMYLOID PRECURSOR PROTEIN; APOLIPOPROTEIN A1; MEMANTINE; REACTIVE NITROGEN SPECIES; REACTIVE OXYGEN METABOLITE; TAU PROTEIN; TUMOR NECROSIS FACTOR ALPHA; VITAMIN D; VITAMIN D BINDING PROTEIN; VITAMIN D RECEPTOR;

AGE DISTRIBUTION; ALZHEIMER DISEASE; AMYLOID PLAQUE; BRAIN ATROPHY; DRUG MEGADOSE; GLUCOSE UTILIZATION; HUMAN; INCIDENCE; LOW DRUG DOSE; MILD COGNITIVE IMPAIRMENT; NERVOUS SYSTEM INFLAMMATION; NEUROFIBRILLARY TANGLE; NEUROIMAGING; NITROSATIVE STRESS; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; OXIDATION REDUCTION STATE; OXIDATIVE STRESS; PRIORITY JOURNAL; REVIEW; RISK FACTOR; SEX RATIO; VITAMIN D DEFICIENCY; VITAMIN D RESPONSIVE ELEMENT; VITAMIN INTAKE; VITAMIN METABOLISM; VITAMIN SUPPLEMENTATION; ANIMAL; METABOLISM;

ALZHEIMER DISEASE; ANIMALS; HUMANS; VITAMIN D DEFICIENCY;

EID: 84937790862     PISSN: 09699961     EISSN: 1095953X     Source Type: Journal    
DOI: 10.1016/j.nbd.2015.06.020     Document Type: Review

References (229)

1. Abreu P., et al. Nitric oxide inhibits tyrosine hydroxylase of rat median eminence. Life Sci. 2000, 67:1941-1946.
2. Adams J.S., Hewison M. Unexpected actions of vitamin D: new perspectives on the regulation of innate and adaptive immunity. Nat. Clin. Pract. Endocrinol. Metab. 2008, 4:80-90.
3. Adam-Vizi V. Production of reactive oxygen species in brain mitochondria: contribution by electron transport chain and non-electron transport chain sources. Antioxid. Redox Signal. 2005, 7:1140-1149.
4. Aluise C.D., et al. Preclinical Alzheimer disease: brain oxidative stress, Abeta peptide and proteomics. Neurobiol. Dis. 2010, 39:221-228.
5. Aluise C.D., et al. Chemo brain (chemo fog) as a potential side effect of doxorubicin administration: role of cytokine-induced, oxidative/nitrosative stress in cognitive dysfunction. Adv. Exp. Med. Biol. 2010, 678:147-156.
6. Aluise C.D., et al. 2-Mercaptoethane sulfonate prevents doxorubicin-induced plasma protein oxidation and TNF-alpha release: implications for the reactive oxygen species-mediated mechanisms of chemobrain. Free Radic. Biol. Med. 2011, 50:1630-1638.
7. Alvarez J.A., et al. Vitamin D status is independently associated with plasma glutathione and cysteine thiol/disulphide redox status in adults. Clin. Endocrinol. 2014, 81:458-466.
8. Amirmansour C., et al. Tyrosine nitration in blood vessels occurs with increasing nitric oxide concentration. Br. J. Pharmacol. 1999, 127:788-794.
9. Anantharaman M., et al. Beta-amyloid mediated nitration of manganese superoxide dismutase: implication for oxidative stress in a APPNLH/NLH X PS-1P264L/P264L double knock-in mouse model of Alzheimer's disease. Am. J. Pathol. 2006, 168:1608-1618.
10. Anastasiou C.A., et al. Vitamin D and cognition: an update of the current evidence. J. Alzheimers Dis. 2014, 42(Suppl. 3):S71-S80.
11. Annweiler C. Vitamin D and Alzheimer's disease: from an intriguing idea to a therapeutic option. Biol Aujourdhui 2014, 208:89-95.
12. Annweiler C., Beauchet O. Vitamin D-mentia: randomized clinical trials should be the next step. Neuroepidemiology 2011, 37:249-258.
13. Annweiler C., Beauchet O. Possibility of a new anti-Alzheimer's disease pharmaceutical composition combining memantine and vitamin D. Drugs Aging 2012, 29:81-91.
14. Annweiler C., et al. Vitamin D and cognitive performance in adults: a systematic review. Eur. J. Neurol. 2009, 16:1083-1089.
15. Annweiler C., et al. Higher vitamin D dietary intake is associated with lower risk of Alzheimer's disease: a 7-year follow-up. J. Gerontol. A Biol. Sci. Med. Sci. 2012, 67:1205-1211.
16. Annweiler C., et al. Low serum vitamin D concentrations in Alzheimer's disease: a systematic review and meta-analysis. J. Alzheimers Dis. 2013, 33:659-674.
17. Annweiler C., et al. Vitamin D and white matter abnormalities in older adults: a cross-sectional neuroimaging study. Eur. J. Neurol. 2014, 21. 1436-e95.
18. Annweiler C., et al. Vitamin D and brain volumetric changes: systematic review and meta-analysis. Maturitas 2014, 78:30-39.
19. Annweiler C., et al. Combination of memantine and vitamin D prevents axon degeneration induced by amyloid-beta and glutamate. Neurobiol. Aging 2014, 35:331-335.
20. Annweiler C., et al. Vitamin D supplements: a novel therapeutic approach for Alzheimer patients. Front. Pharmacol. 2014, 5:6.
21. Annweiler C., et al. Vitamin D and white matter abnormalities in older adults: a quantitative volumetric analysis of brain MRI. Exp. Gerontol. 2015, 63C:41-47.
22. Annweiler C., et al. 'Vitamin D and cognition in older adults': updated international recommendations. J. Intern. Med. 2015, 277:45-57.
23. Anttila T., et al. Midlife income, occupation, APOE status, and dementia: a population-based study. Neurology 2002, 59:887-893.
24. Autier P., Gandini S. Vitamin D supplementation and total mortality: a meta-analysis of randomized controlled trials. Arch. Intern. Med. 2007, 167:1730-1737.
25. Badiola N., et al. Activation of caspase-8 by tumour necrosis factor receptor 1 is necessary for caspase-3 activation and apoptosis in oxygen-glucose deprived cultured cortical cells. Neurobiol. Dis. 2009, 35:438-447.
26. Barone E., Butterfield D.A. Insulin resistance in Alzheimer disease: is heme oxygenase-1 an Achilles' heel?. Neurobiol. Dis. 2015, 84:69-77.
27. Becker A., et al. Transient prenatal vitamin D deficiency is associated with subtle alterations in learning and memory functions in adult rats. Behav. Brain Res. 2005, 161:306-312.
28. Bellia A., et al. Serum 25-hydroxyvitamin D levels are inversely associated with systemic inflammation in severe obese subjects. Intern. Emerg. Med. 2013, 8:33-40.
29. Berridge M.J. Calcium hypothesis of Alzheimer's disease. Pflugers Arch. 2010, 459:441-449.
30. Berridge M.J. Calcium signalling and Alzheimer's disease. Neurochem. Res. 2011, 36:1149-1156.
31. Berridge M.J. Calcium regulation of neural rhythms, memory and Alzheimer's disease. J. Physiol. 2014, 592:281-293.
32. Berti V., et al. Nutrient patterns and brain biomarkers of Alzheimer's disease in cognitively normal individuals. J. Nutr. Health Aging 2015, 19:413-423.
33. Binkley N., et al. Low vitamin D status: definition, prevalence, consequences, and correction. Rheum. Dis. Clin. N. Am. 2012, 38:45-59.
34. Bischoff-Ferrari H.A. "Vitamin D - why does it matter?" - defining vitamin D deficiency and its prevalence. Scand. J. Clin. Lab. Invest. Suppl. 2012, 243:3-6.
35. Bonda D.J. Neuronal failure in Alzheimer disease: a view through the oxidative stress looking-glass. Neurosci. Bull. 2014, 30:243-252.
36. Bosse Y., et al. Asthma and genes encoding components of the vitamin D pathway. Respir. Res. 2009, 10:98.
37. Bourre J.M. Effects of nutrients (in food) on the structure and function of the nervous system: update on dietary requirements for brain. Part 1: micronutrients. J. Nutr. Health Aging 2006, 10:377-385.
38. Braak H., Braak E. Staging of Alzheimer's disease-related neurofibrillary changes. Neurobiol. Aging 1995, 16:271-278. (discussion 278-84).
39. Brandt R., et al. Tau alteration and neuronal degeneration in tauopathies: mechanisms and models. Biochim. Biophys. Acta 2005, 1739:331-354.
40. Brewer L.D., et al. Vitamin D hormone confers neuroprotection in parallel with downregulation of L-type calcium channel expression in hippocampal neurons. J. Neurosci. 2001, 21:98-108.
41. 2+-mediated hippocampal biomarkers of aging. Cell Calcium 2006, 40:277-286.
42. Briones T.L., Darwish H. Vitamin D mitigates age-related cognitive decline through the modulation of pro-inflammatory state and decrease in amyloid burden. J. Neuroinflammation 2012, 9:244.
43. Briones T.L., Darwish H. Decrease in age-related tau hyperphosphorylation and cognitive improvement following vitamin D supplementation are associated with modulation of brain energy metabolism and redox state. Neuroscience 2014, 262:143-155.
44. Brouwer-Brolsma E.M., de Groot L.C. Vitamin D and cognition in older adults: an update of recent findings. Curr. Opin. Clin. Nutr. Metab. Care 2015, 18:11-16.
45. Brouwer-Brolsma E.M., et al. Serum 25-hydroxyvitamin D is associated with cognitive executive function in Dutch prefrail and frail elderly: a cross-sectional study exploring the associations of 25-hydroxyvitamin D with glucose metabolism, cognitive performance and depression. J. Am. Med. Dir. Assoc. 2013, 14(852):e9-e17.
46. Burne T.H., et al. Transient prenatal vitamin D deficiency is associated with hyperlocomotion in adult rats. Behav. Brain Res. 2004, 154:549-555.
47. Butterfield D.A. The 2013 SFRBM Discovery Award: selected discoveries from the Butterfield Laboratory of Oxidative Stress and its sequela in brain in cognitive disorders exemplified by Alzheimer disease and chemotherapy induced cognitive impairment. Free Radic. Biol. Med. 2014, 74:157-174.
48. Butterfield D.A., Dalle-Donne I. Redox proteomics: from protein modifications to cellular dysfunction and disease. Mass Spectrom. Rev. 2014, 33:1-6.
49. Butterfield D.A., Lauderback C.M. Lipid peroxidation and protein oxidation in Alzheimer's disease brain: potential causes and consequences involving amyloid beta-peptide-associated free radical oxidative stress. Free Radic. Biol. Med. 2002, 32:1050-1060.
50. Butterfield D.A., Stadtman E.R. Protein oxidation processes in aging brain. Adv. Cell Aging Gerontol. 1997, 2:161-191.
51. Butterfield D.A., et al. Evidence of oxidative damage in Alzheimer's disease brain: central role for amyloid beta-peptide. Trends Mol. Med. 2001, 7:548-554.
52. Butterfield D.A., et al. Elevated levels of 3-nitrotyrosine in brain from subjects with amnestic mild cognitive impairment: implications for the role of nitration in the progression of Alzheimer's disease. Brain Res. 2007, 1148:243-248.
53. Butterfield D.A., et al. Involvements of the lipid peroxidation product, HNE, in the pathogenesis and progression of Alzheimer's disease. Biochim. Biophys. Acta 2010, 1801:924-929.
54. Butterfield D.A., et al. Amyloid beta-peptide (1-42)-induced oxidative stress in Alzheimer disease: importance in disease pathogenesis and progression. Antioxid. Redox Signal. 2013, 19:823-835.
55. Butterfield D.A., et al. Elevated risk of type 2 diabetes for development of Alzheimer disease: a key role for oxidative stress in brain. Biochim. Biophys. Acta 2014, 1842:1693-1706.
56. Butterfield D.A., et al. Mass spectrometry and redox proteomics: applications in disease. Mass Spectrom. Rev. 2014, 33:277-301.
57. Calabrese V., et al. Nitric oxide and cellular stress response in brain aging and neurodegenerative disorders: the role of vitagenes. In Vivo 2004, 18:245-267.
58. Calabrese V., et al. Redox modulation of heat shock protein expression by acetylcarnitine in aging brain: relationship to antioxidant status and mitochondrial function. Antioxid. Redox Signal. 2006, 8:404-416.
59. Calabrese V., et al. Redox regulation of cellular stress response in neurodegenerative disorders. Ital. J. Biochem. 2006, 55:263-282.
60. Calabrese V., et al. Nitrosative stress, cellular stress response, and thiol homeostasis in patients with Alzheimer's disease. Antioxid. Redox Signal. 2006, 8:1975-1986.
61. Camandola S., Mattson M.P. Aberrant subcellular neuronal calcium regulation in aging and Alzheimer's disease. Biochim. Biophys. Acta 2011, 1813:965-973.
62. Carlberg C. Genome-wide (over)view on the actions of vitamin D. Front. Physiol. 2014, 5:167.
63. Carlberg C. The physiology of vitamin D-far more than calcium and bone. Front. Physiol. 2014, 5:335.
64. Carlberg C., Molnar F. Detailed molecular understanding of agonistic and antagonistic vitamin D receptor ligands. Curr. Top. Med. Chem. 2006, 6:1243-1253.
65. Carlberg C., Molnar F. Current status of vitamin D signaling and its therapeutic applications. Curr. Top. Med. Chem. 2012, 12:528-547.
66. Cass W.A., et al. Calcitriol protects against the dopamine- and serotonin-depleting effects of neurotoxic doses of methamphetamine. Ann. N. Y. Acad. Sci. 2006, 1074:261-271.
67. Cass W.A., et al. Evoked dopamine overflow is augmented in the striatum of calcitriol treated rats. Neurochem. Int. 2012, 60:186-191.
68. Castegna A., et al. Proteomic identification of nitrated proteins in Alzheimer's disease brain. J. Neurochem. 2003, 85:1394-1401.
69. Castegna A., et al. Modulation of phospholipid asymmetry in synaptosomal membranes by the lipid peroxidation products, 4-hydroxynonenal and acrolein: implications for Alzheimer's disease. Brain Res. 2004, 1004:193-197.
70. 3 megadose reduces inflammatory markers. Exp. Gerontol. 2015, 66:10-16.
71. Chagas C.E., et al. Focus on vitamin D, inflammation and type 2 diabetes. Nutrients 2012, 4:52-67.
72. Charier D., et al. Memantine plus vitamin D prevents axonal degeneration caused by lysed blood. ACS Chem. Neurosci. 2015, 6:393-397.
73. 3 upregulated protein 1 (VDUP1) is a regulator for redox signaling and stress-mediated diseases. J. Dermatol. 2006, 33:662-669.
74. Corder E.H., et al. Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer's disease in late onset families. Science 1993, 261:921-923.
75. Cui X., et al. Maternal vitamin D depletion alters neurogenesis in the developing rat brain. Int. J. Dev. Neurosci. 2007, 25:227-232.
76. Cui X., et al. Vitamin D and the brain: key questions for future research. J. Steroid Biochem. Mol. Biol. 2015, 148:305-309.
77. Dasuri K., et al. Oxidative stress, neurodegeneration, and the balance of protein degradation and protein synthesis. Free Radic. Biol. Med. 2013, 62:170-185.
78. Daubner S.C., et al. Tyrosine hydroxylase and regulation of dopamine synthesis. Arch. Biochem. Biophys. 2011, 508:1-12.
79. de la Monte S.M., et al. Therapeutic rescue of neurodegeneration in experimental type 3 diabetes: relevance to Alzheimer's disease. J. Alzheimers Dis. 2006, 10:89-109.
80. Deby C., Goutier R. New perspectives on the biochemistry of superoxide anion and the efficiency of superoxide dismutases. Biochem. Pharmacol. 1990, 39:399-405.
81. Deeb K.K., et al. Vitamin D signalling pathways in cancer: potential for anticancer therapeutics. Nat. Rev. Cancer 2007, 7:684-700.
82. DeLuca H.F. The metabolism and functions of vitamin D. Adv. Exp. Med. Biol. 1986, 196:361-375.
83. Diaz L., et al. Calcitriol inhibits TNF-alpha-induced inflammatory cytokines in human trophoblasts. J. Reprod. Immunol. 2009, 81:17-24.
84. Dickens A.P., et al. Vitamin D, cognitive dysfunction and dementia in older adults. CNS Drugs 2011, 25:629-639.
85. Dorey E., et al. Apolipoprotein E, amyloid-beta, and neuroinflammation in Alzheimer's disease. Neurosci. Bull. 2014, 30:317-330.
86. Durk M.R., et al. 1alpha,25-Dihydroxyvitamin D-3 reduces cerebral amyloid-beta accumulation and improves cognition in mouse models of Alzheimer's disease. J. Neurosci. 2014, 34:7091-7101.
87. Dursun E., et al. Beta amyloid suppresses the expression of the vitamin D receptor gene and induces the expression of the vitamin D catabolic enzyme gene in hippocampal neurons. Dement. Geriatr. Cogn. Disord. 2013, 36:76-86.
88. Dusso A.S., Brown A.J. Mechanism of vitamin D action and its regulation. Am. J. Kidney Dis. 1998, 32:S13-S24.
89. Erickson M.A., et al. Lipopolysaccharide impairs amyloid beta efflux from brain: altered vascular sequestration, cerebrospinal fluid reabsorption, peripheral clearance and transporter function at the blood-brain barrier. J. Neuroinflammation 2012, 9:150.
90. Etgen T., et al. Mild cognitive impairment and dementia: the importance of modifiable risk factors. Dtsch. Arztebl. Int. 2011, 108:743-750.
91. Etgen T., et al. Vitamin D deficiency, cognitive impairment and dementia: a systematic review and meta-analysis. Dement. Geriatr. Cogn. Disord. 2012, 33:297-305.
92. Eyles D.W., et al. Vitamin D, effects on brain development, adult brain function and the links between low levels of vitamin D and neuropsychiatric disease. Front. Neuroendocrinol. 2013, 34:47-64.
93. Farid K., et al. Correlation between serum 25-hydroxyvitamin D concentrations and regional cerebral blood flow in degenerative dementia. Nucl. Med. Commun. 2012, 33:1048-1052.
94. Farrer L.A., et al. Effects of age, sex, and ethnicity on the association between apolipoprotein E genotype and Alzheimer disease, a meta-analysis. APOE and Alzheimer Disease Meta Analysis Consortium. JAMA 1997, 278:1349-1356.
95. Fedirko V., et al. Effects of vitamin D and calcium supplementation on markers of apoptosis in normal colon mucosa: a randomized, double-blind, placebo-controlled clinical trial. Cancer Prev. Res. (Phila.) 2009, 2:213-223.
96. Fedirko V., et al. Effects of supplemental vitamin D and calcium on oxidative DNA damage marker in normal colorectal mucosa: a randomized clinical trial. Cancer Epidemiol. Biomarkers Prev. 2010, 19:280-291.
97. Feeney M.B., Schoneich C. Tyrosine modifications in aging. Antioxid. Redox Signal. 2012, 17:1571-1579.
98. Fernandes de Abreu D.A., et al. Vitamin D, a neuro-immunomodulator: implications for neurodegenerative and autoimmune diseases. Psychoneuroendocrinology 2009, 34(Suppl. 1):S265-S277.
99. Fiala M. Re-balancing of inflammation and abeta immunity as a therapeutic for Alzheimer's disease-view from the bedside. CNS Neurol. Disord. Drug Targets 2010, 9:192-196.
100. Floyd R.A. Antioxidants, oxidative stress, and degenerative neurological disorders. Proc. Soc. Exp. Biol. Med. 1999, 222:236-245.
101. Fridovich I. Biological effects of the superoxide radical. Arch. Biochem. Biophys. 1986, 247:1-11.
102. Furman I., et al. Differential expression of M-CSF, LIF, and TNF-alpha genes in normal and malignant rat glial cells: regulation by lipopolysaccharide and vitamin D. J. Neurosci. Res. 1996, 46:360-366.
103. Garwood C., Faizullabhoy A., Wharton S.B., Ince P.G., Heath P.R., Shaw P.J., Baxter L., Gelsthorpe C., Forster G., Matthews F.E., Brayne C., Simpson J.E., Cognitive Function M.R.C., Ageing Neuropathology Study Group Calcium dysregulation in relation to Alzheimer-type pathology in the ageing brain. Neuropathol. Appl. Neurobiol. 2013, 39:788-799.
104. Gezen-Ak D., et al. Association between vitamin D receptor gene polymorphism and Alzheimer's disease. Tohoku J. Exp. Med. 2007, 212:275-282.
105. Giulietti A., et al. Monocytes from type 2 diabetic patients have a pro-inflammatory profile. 1,25-Dihydroxyvitamin D(3) works as anti-inflammatory. Diabetes Res. Clin. Pract. 2007, 77:47-57.
106. Golabek A., et al. Amyloid beta binding proteins in vitro and in normal human cerebrospinal fluid. Neurosci. Lett. 1995, 191:79-82.
107. Groves N.J., et al. Vitamin D as a neurosteroid affecting the developing and adult brain. Annu. Rev. Nutr. 2014, 34:117-141.
108. Halliwell B. Free radicals and antioxidants - quo vadis?. Trends Pharmacol. Sci. 2011, 32:125-130.
109. Halliwell B., Gutteridge J.M. Oxygen toxicity, oxygen radicals, transition metals and disease. Biochem. J. 1984, 219:1-14.
110. Harman D. Aging: overview. Ann. N. Y. Acad. Sci. 2001, 928:1-21.
111. Haussler M.R., et al. Vitamin D receptor: molecular signaling and actions of nutritional ligands in disease prevention. Nutr. Rev. 2008, 66:S98-S112.
112. Hensley K., et al. A model for beta-amyloid aggregation and neurotoxicity based on free radical generation by the peptide: relevance to Alzheimer disease. Proc. Natl. Acad. Sci. U. S. A. 1994, 91:3270-3274.
113. Hensley K., et al. A model for beta-amyloid aggregation and neurotoxicity based on the free radical generating capacity of the peptide: implications of "molecular shrapnel" for Alzheimer's disease. Proc. West. Pharmacol. Soc. 1995, 38:113-120.
114. Hensley K., et al. Brain regional correspondence between Alzheimer's disease histopathology and biomarkers of protein oxidation. J. Neurochem. 1995, 65:2146-2156.
115. Holick M.F. Sunlight and vitamin D for bone health and prevention of autoimmune diseases, cancers, and cardiovascular disease. Am. J. Clin. Nutr. 2004, 80:1678S-1688S.
116. Holick M.F. Vitamin D deficiency. N. Engl. J. Med. 2007, 357:266-281.
117. Hooshmand B., et al. Vitamin D in relation to cognitive impairment, cerebrospinal fluid biomarkers, and brain volumes. J. Gerontol. A Biol. Sci. Med. Sci. 2014, 69:1132-1138.
118. Hopkins M.H., et al. Effects of supplemental vitamin D and calcium on biomarkers of inflammation in colorectal adenoma patients: a randomized, controlled clinical trial. Cancer Prev. Res. (Phila.) 2011, 4:1645-1654.
119. Hyka N., et al. Apolipoprotein A-I inhibits the production of interleukin-1beta and tumor necrosis factor-alpha by blocking contact-mediated activation of monocytes by T lymphocytes. Blood 2001, 97:2381-2389.
120. Ischiropoulos H. Protein tyrosine nitration-an update. Arch. Biochem. Biophys. 2009, 484:117-121.
121. Jack C.R., et al. Brain atrophy rates predict subsequent clinical conversion in normal elderly and amnestic MCI. Neurology 2005, 65:1227-1231.
122. John W.G., et al. Hypovitaminosis D is associated with reductions in serum apolipoprotein A-I but not with fasting lipids in British Bangladeshis. Am. J. Clin. Nutr. 2005, 82:517-522.
123. Johnson J.K., et al. Initiation and propagation stages of beta-amyloid are associated with distinctive apolipoprotein E, age, and gender profiles. Brain Res. 1998, 798:18-24.
124. Kawano M., et al. Marked decrease of plasma apolipoprotein AI and AII in Japanese patients with late-onset non-familial Alzheimer's disease. Clin. Chim. Acta 1995, 239:209-211.
125. Keeney J.T., et al. Dietary vitamin D deficiency in rats from middle to old age leads to elevated tyrosine nitration and proteomics changes in levels of key proteins in brain: implications for low vitamin D-dependent age-related cognitive decline. Free Radic. Biol. Med. 2013, 65C:324-334.
126. Keeney J.T., et al. Apolipoprotein A-I: insights from redox proteomics for its role in neurodegeneration. Proteomics Clin. Appl. 2013, 7:109-122.
127. Keilhoff G., et al. Haloperidol normalized prenatal vitamin D depletion-induced reduction of hippocampal cell proliferation in adult rats. Neurosci. Lett. 2010, 476:94-98.
128. Kennel K.A., et al. Vitamin D deficiency in adults: when to test and how to treat. Mayo Clin. Proc. 2010, 85:752-757. (quiz 757-8).
129. Kerr D.C., et al. Associations between vitamin D levels and depressive symptoms in healthy young adult women. Psychiatry Res. 2015, 227:46-51.
130. Kesby J.P., et al. The effects of vitamin D on brain development and adult brain function. Mol. Cell. Endocrinol. 2011, 347:121-127.
131. Klamt F., et al. Time-related increase in mitochondrial superoxide production, biomolecule damage and antioxidant enzyme activities in cortical astrocyte cultures. Neuroreport 2002, 13:1515-1518.
132. Ko L.W., et al. Recent advances in experimental modeling of the assembly of tau filaments. Biochim. Biophys. Acta 2005, 1739:125-139.
133. Koldamova R.P., et al. Apolipoprotein A-I directly interacts with amyloid precursor protein and inhibits A beta aggregation and toxicity. Biochemistry 2001, 40:3553-3560.
134. 3 upregulated protein 1 suppresses TNF-alpha-induced NF-kappaB activation in hepatocarcinogenesis. J. Immunol. 2010, 185:3980-3989.
135. Latimer C.S., et al. Vitamin D prevents cognitive decline and enhances hippocampal synaptic function in aging rats. Proc. Natl. Acad. Sci. U. S. A. 2014, 111:E4359-E4366.
136. Lauderback The glutamate transporter, Glt-1, is oxidatively modified by 4-hydroxy-2-nonenal in the Alzheimer's disease brain: the role of Abeta1-42. J. Neurochem. 2001, 78:413-416.
137. Lee Y.H., et al. Vitamin D receptor polymorphisms and susceptibility to Parkinson's disease and Alzheimer's disease: a meta-analysis. Neurol. Sci. 2014, 35:1947-1953.
138. Lewis T.L., et al. Overexpression of human apolipoprotein A-I preserves cognitive function and attenuates neuroinflammation and cerebral amyloid angiopathy in a mouse model of Alzheimer disease. J. Biol. Chem. 2010, 285:36958-36968.
139. Liu H.C., et al. Proteomic identification of lower apolipoprotein A-I in Alzheimer's disease. Dement. Geriatr. Cogn. Disord. 2006, 21:155-161.
140. Liu C.C., et al. Apolipoprotein E and Alzheimer disease: risk, mechanisms and therapy. Nat. Rev. Neurol. 2013, 9:106-118.
141. Llewellyn D.J., Lang I.A., Langa K.M., Melzer D. Vitamin D and cognitive impairment in the elderly U.S. population. J Gerontol A Biol Sci Med Sci 2011, 66:59-65.
142. Looker A.C., et al. Vitamin D status: United States, 2001-2006. NCHS Data Brief 2011, 1-8.
143. MacMillan-Crow L.A., et al. Peroxynitrite-mediated inactivation of manganese superoxide dismutase involves nitration and oxidation of critical tyrosine residues. Biochemistry 1998, 37:1613-1622.
144. 2+ homeostasis and cell death. J. Neurosci. 1995, 15:6239-6249.
145. 3 interacts with curcuminoids to stimulate amyloid-beta clearance by macrophages of Alzheimer's disease patients. J. Alzheimers Dis. 2009, 17:703-717.
146. Masters C.L., Selkoe D.J. Biochemistry of amyloid β-protein: synaptic and network dysfunction. Cold Spring Harb. Perspect. Med. 2011, 2:a006262.
147. Mattson M.P. Calcium and neuronal injury in Alzheimer's disease. Contributions of beta-amyloid precursor protein mismetabolism, free radicals, and metabolic compromise. Ann. N. Y. Acad. Sci. 1994, 747:50-76.
148. Merched A., et al. Decreased high-density lipoprotein cholesterol and serum apolipoprotein AI concentrations are highly correlated with the severity of Alzheimer's disease. Neurobiol. Aging 2000, 21:27-30.
149. Millet P., et al. Role of vitamin D in the physiopathology of neurodegenerative diseases. Biol Aujourdhui 2014, 208:77-88.
150. 3 promotes the recovery of amyloid-beta phagocytosis by Alzheimer's disease macrophages. J. Alzheimers Dis. 2012, 29:51-62.
151. 1 retune the balance between amyloid-beta phagocytosis and inflammation in Alzheimer's disease patients. J. Alzheimers Dis. 2013, 34:155-170.
152. Mohmmad Abdul H., et al. Mutations in amyloid precursor protein and presenilin-1 genes increase the basal oxidative stress in murine neuronal cells and lead to increased sensitivity to oxidative stress mediated by amyloid beta-peptide (1-42), HO and kainic acid: implications for Alzheimer's disease. J. Neurochem. 2006, 96:1322-1335.
153. Moon M., et al. Vitamin D-binding protein interacts with Abeta and suppresses Abeta-mediated pathology. Cell Death Differ. 2013, 20:630-638.
154. Mortensen E.L., Hogh P. A gender difference in the association between APOE genotype and age-related cognitive decline. Neurology 2001, 57:89-95.
155. Mosconi L. Brain glucose metabolism in the early and specific diagnosis of Alzheimer's disease. FDG-PET studies in MCI and AD. Eur. J. Nucl. Med. Mol. Imaging 2005, 32:486-510.
156. Mosconi L., et al. Nutrient intake and brain biomarkers of Alzheimer's disease in at-risk cognitively normal individuals: a cross-sectional neuroimaging pilot study. BMJ Open 2014, 4:e004850.
157. Muenchhoff J., et al. Plasma protein profiling of mild cognitive impairment and Alzheimer's disease across two independent cohorts. J. Alzheimers Dis. 2015, 43:1355-1373.
158. Nair R., Maseeh A. Vitamin D: the "sunshine" vitamin. J. Pharmacol. Pharmacother. 2012, 3:118-126.
159. 3-induced responses: role of reactive oxygen species. J. Cell. Biochem. 2006, 99:1572-1581.
160. 3 inducible transcription factor and its role in the vitamin D action. Endocr. Regul. 2004, 38:29-38.
161. 3 triggers an anti-inflammatory response in brain pericytes. J. Alzheimers Dis. 2014, 42:789-799.
162. Nunomura A., et al. Oxidative stress is the earliest event in Alzheimer disease. J. Neuropathol. Exp. Neurol. 2001, 60:759-767.
163. Olde Rikkert M.G., et al. Differences in nutritional status between very mild Alzheimer's disease patients and healthy controls. J. Alzheimers Dis. 2014, 41:261-271.
164. O'Loan J., et al. Vitamin D deficiency during various stages of pregnancy in the rat; its impact on development and behaviour in adult offspring. Psychoneuroendocrinology 2007, 32:227-234.
165. Owen J.B., et al. Oxidative modification to LDL receptor-related protein 1 in hippocampus from subjects with Alzheimer disease: implications for Abeta accumulation in AD brain. Free Radic. Biol. Med. 2010, 49:1798-1803.
166. Payami H., et al. Gender difference in apolipoprotein E-associated risk for familial Alzheimer disease: a possible clue to the higher incidence of Alzheimer disease in women. Am. J. Hum. Genet. 1996, 58:803-811.
167. Pedros I., et al. Early alterations in energy metabolism in the hippocampus of APPswe/PS1dE9 mouse model of Alzheimer's disease. Biochim. Biophys. Acta 2014, 1842:1556-1566.
168. 3 supplementation. Pharmacol. Biochem. Behav. 2010, 95:216-222.
169. Perluigi M., et al. Redox proteomics in aging rat brain: involvement of mitochondrial reduced glutathione status and mitochondrial protein oxidation in the aging process. J. Neurosci. Res. 2010, 88:3498-3507.
170. Perluigi M., et al. Redox proteomics and the dynamic molecular landscape of the aging brain. Ageing Res. Rev. 2014, 13:75-89.
171. Peterson C.A., Heffernan M.E. Serum tumor necrosis factor-alpha concentrations are negatively correlated with serum 25(OH)D concentrations in healthy women. J. Inflamm. 2008, 5:10.
172. Pocernich C.B., Butterfield D.A. Elevation of glutathione as a therapeutic strategy in Alzheimer disease. Biochim. Biophys. Acta 2012, 1822:625-630.
173. Poon H.F., et al. Free radicals and brain aging. Clin. Geriatr. Med. 2004, 20:329-359.
174. Qiu C., et al. Risk and protective effects of the APOE gene towards Alzheimer's disease in the Kungsholmen project: variation by age and sex. J. Neurol. Neurosurg. Psychiatry 2004, 75:828-833.
175. Quazi F., Molday R.S. Lipid transport by mammalian ABC proteins. Essays Biochem. 2011, 50:265-290.
176. Rader D.J., Daugherty A. Translating molecular discoveries into new therapies for atherosclerosis. Nature 2008, 451:904-913.
177. Ramagopalan S.V., et al. A ChIP-seq defined genome-wide map of vitamin D receptor binding: associations with disease and evolution. Genome Res. 2010, 20:1352-1360.
178. Rapoport S.I., Nelson P.T. Biomarkers and evolution in Alzheimer disease. Prog. Neurobiol. 2011, 95:510-513.
179. Raygani A.V., et al. Association between apolipoprotein E polymorphism and serum lipid and apolipoprotein levels with Alzheimer's disease. Neurosci. Lett. 2006, 408:68-72.
180. 3-MARRS (membrane associated, rapid response steroid-binding), a novel vitamin D receptor, in growth inhibition of breast cancer cells. Exp. Cell Res. 2010, 316:695-703.
181. Robinson J.G., Booth B. Statin use and lipid levels in older adults: National Health and Nutrition Examination Survey, 2001 to 2006. J. Clin. Lipidol. 2010, 4:483-490.
182. Saczynski J.S., et al. The relation between apolipoprotein A-I and dementia: the Honolulu-Asia aging study. Am. J. Epidemiol. 2007, 165:985-992.
183. 3 down-regulates monocyte TLR expression and triggers hyporesponsiveness to pathogen-associated molecular patterns. Eur. J. Immunol. 2006, 36:361-370.
184. Sakurai T., et al. Lower vitamin D is associated with white matter hyperintensity in elderly women with Alzheimer disease and amnestic mild cognitive impairment. J. Am. Geriatr. Soc. 2014, 62:1993-1994.
185. 3 administration to 6-hydroxydopamine-lesioned rats increases glial cell line-derived neurotrophic factor and partially restores tyrosine hydroxylase expression in substantia nigra and striatum. J. Neurosci. Res. 2009, 87:723-732.
186. Sanders L.H. Mitochondrial DNA damage: molecular marker of vulnerable nigral neurons in Parkinson's disease. Neurobiol. Dis. 2014, 70:214-223.
187. Scheff S.W., et al. Is synaptic loss a unique hallmark of Alzheimer disease?. Biochem. Pharmacol. 2014, 88:517-528.
188. Schlogl M., Holick M.F. Vitamin D and neurocognitive function. Clin. Interv. Aging 2014, 9:559-568.
189. Schneider A.L., et al. Vitamin D and cognitive function and dementia risk in a biracial cohort: the ARIC Brain MRI Study. Eur. J. Neurol. 2014, 21(1211-8):e69-e70.
190. Schneider-Brachert W., et al. Compartmentalization of TNF receptor 1 signaling: internalized TNF receptosomes as death signaling vesicles. Immunity 2004, 21:415-428.
191. Schulz E., et al. Mitochondrial redox signaling: interaction of mitochondrial reactive oxygen species with other sources of oxidative stress. Antioxid. Redox Signal. 2014, 20:308-324.
192. Scialo F., et al. Regulation of lifespan by the mitochondrial electron transport chain: reactive oxygen species-dependent and reactive oxygen species-independent mechanisms. Antioxid. Redox Signal. 2013, 19:1953-1969.
193. Selkoe D.J. Alzheimer's disease: genes, proteins, and therapy. Physiol. Rev. 2001, 81:741-766.
194. Seripa D., et al. The genetics of the human APOE polymorphism. Rejuvenation Res. 2011, 14:491-500.
195. Sies H. Oxidative stress: oxidants and antioxidants. Exp. Physiol. 1997, 82:291-295.
196. Sies H. Oxidative stress: a concept in redox biology and medicine. Redox Biol. 2015, 4C:180-183.
197. Singh T., Newman A.B. Inflammatory markers in population studies of aging. Ageing Res. Rev. 2011, 10:319-329.
198. Sompol P., et al. A neuronal model of Alzheimer's disease: an insight into the mechanisms of oxidative stress-mediated mitochondrial injury. Neuroscience 2008, 153:120-130.
199. 3 treatment results in increased choline acetyltransferase activity in specific brain nuclei. Endocrinology 1986, 118:1433-1439.
200. Sperling R.A., et al. Toward defining the preclinical stages of Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement. 2011, 7:280-292.
201. Stadtman E.R., Berlett B.S. Reactive oxygen-mediated protein oxidation in aging and disease. Drug Metab. Rev. 1998, 30:225-243.
202. Steen E., et al. Impaired insulin and insulin-like growth factor expression and signaling mechanisms in Alzheimer's disease-is this type 3 diabetes?. J. Alzheimers Dis. 2005, 7:63-80.
203. 2 followed by intranasal insulin in Alzheimer's disease. J. Alzheimers Dis. 2011, 26:477-484.
204. Stubbs J.R., et al. Cholecalciferol supplementation alters calcitriol-responsive monocyte proteins and decreases inflammatory cytokines in ESRD. J. Am. Soc. Nephrol. 2010, 21:353-361.
205. Sullivan N.J., et al. UV light B-mediated inhibition of skin catalase activity promotes Gr-1+ CD11b+ myeloid cell expansion. J. Invest. Dermatol. 2012, 132:695-702.
206. Sultana R., Butterfield D.A. Role of oxidative stress in the progression of Alzheimer's disease. J. Alzheimers Dis. 2010, 19:341-353.
207. Sultana R., Butterfield D.A. Oxidative modification of brain proteins in Alzheimer's disease: perspective on future studies based on results of redox proteomics studies. J. Alzheimers Dis. 2013, 33(Suppl. 1):S243-S251.
208. Sultana R., et al. Identification of nitrated proteins in Alzheimer's disease brain using a redox proteomics approach. Neurobiol. Dis. 2006, 22:76-87.
209. Sultana R., et al. Lipid peroxidation triggers neurodegeneration: a redox proteomics view into the Alzheimer disease brain. Free Radic. Biol. Med. 2013, 62:157-169.
210. Surmeli N.B., et al. Peroxynitrite mediates active site tyrosine nitration in manganese superoxide dismutase. Evidence of a role for the carbonate radical anion. J. Am. Chem. Soc. 2010, 51:622-629.
211. Swomley A.M., Förster S., Keeney J.T., Triplett J., Zhang Z., Sultana R., Butterfield D.A. Abeta, oxidative stress in Alzheimer disease: evidence based on proteomic studies. Biochim Biophys Acta 2014, 1842:1248-1257.
212. Taghizadeh M., Talaei S.A., Djazayeri A., Salami M. Vitamin D supplementation restores suppressed synaptic plasticity in Alzheimer's disease. Nutr Neurosci 2014, 17:172-177.
213. Tangpong J., Sompol P., St Clair W., Butterfield D.A., St Clair D.K. Tumor necrosis factor alpha-mediated nitriv oxide production enhances manganese superoxide dismutase nitration and mitochondrial dysfunction in primary neurons: an insight into the role of glial cells. Neuroscience 2008, 151:622-629.
214. Tekes K., et al. Influence of neonatal vitamin A or vitamin D treatment on the concentration of biogenic amines and their metabolites in the adult rat brain. Horm. Metab. Res. 2009, 41:277-280.
215. Valko M., et al. Free radicals and antioxidants in normal physiological functions and human disease. Int. J. Biochem. Cell Biol. 2007, 39:44-84.
216. van Duijn C.M., et al. Familial aggregation of Alzheimer's disease and related disorders: a collaborative re-analysis of case-control studies. J. Epidemiol. 1991, 20(Suppl. 2):S13-S20.
217. Verdile G., et al. The role of type 2 diabetes in neurodegeneration. Neurobiol. Dis. 2015, 84:22-38.
218. Vos S.J., et al. Prevalence and prognosis of Alzheimer disease at the mild cognitive impairment stage. Brain 2015, 138(Pt5):1327-1338.
219. Wang J.Y., et al. Vitamin D(3) attenuates 6-hydroxydopamine-induced neurotoxicity in rats. Brain Res. 2001, 904:67-75.
220. Wang T.J., et al. Common genetic determinants of vitamin D insufficiency: a genome-wide association study. Lancet 2010, 376:180-188.
221. Wang L., et al. Vitamin D receptor and Alzheimer's disease: a genetic and functional study. Neurobiol. Aging 2012, 33(1844):e1-e9.
222. Watson R.R., Preedy V.R. Bioactive Food as Dietary Interventions for the Aging Population 2013, Elsevier/Academic Press, Boston.
223. Wisniewski T., et al. Conformational mimicry in Alzheimer's disease. Role of apolipoproteins in amyloidogenesis. Am. J. Pathol. 1995, 147:238-244.
224. Yaari R., Corey-Bloom J. Alzheimer's disease. Semin. Neurol. 2007, 27:32-41.
225. Yao J., et al. Mitochondrial bioenergetic deficit precedes Alzheimer's pathology in female mouse model of Alzheimer's disease. Proc. Natl. Acad. Sci. U. S. A. 2009, 106:14670-14675.
226. Zhao L., et al. Insulin-degrading enzyme as a downstream target of insulin receptor signaling cascade: implications for Alzheimer's disease intervention. J. Neurosci. 2004, 24:11120-11126.
227. 3). Hippocampus 2012, 22:421-433.
228. Zittermann A., et al. Vitamin D deficiency and mortality. Curr. Opin. Clin. Nutr. Metab. Care 2009, 12:634-639.
229. Zittermann A., et al. Vitamin D deficiency and mortality risk in the general population: a meta-analysis of prospective cohort studies. Am. J. Clin. Nutr. 2012, 95:91-100.